Manchester Metropolitan University's Research Repository

    Nanomolar-potency small molecule inhibitor of STAT5 protein

    Cumaraswamy, AA, Lewis, AM, Geletu, M, Todic, A, Diaz, DB, Cheng, XR, Brown, CE, Laister, RC, Muench, D, Kerman, K, Grimes, HL, Minden, MD and Gunning, PT (2014) Nanomolar-potency small molecule inhibitor of STAT5 protein. ACS Medicinal Chemistry Letters, 5 (11). pp. 1202-1206. ISSN 1948-5875

    Accepted Version
    Download (2MB) | Preview


    © 2014 American Chemical Society. We herein report the design and synthesis of the first nanomolar binding inhibitor of STAT5 protein. Lead compound 13a, possessing a phosphotyrosyl-mimicking salicylic acid group, potently and selectively binds to STAT5 over STAT3, inhibits STAT5-SH2 domain complexation events in vitro, silences activated STAT5 in leukemic cells, as well as STAT5's downstream transcriptional targets, including MYC and MCL1, and, as a result, leads to apoptosis. We believe 13a represents a useful probe for interrogating STAT5 function in cells as well as being a potential candidate for advanced preclinical trials.

    Impact and Reach


    Activity Overview
    6 month trend
    6 month trend

    Additional statistics for this dataset are available via IRStats2.


    Repository staff only

    Edit record Edit record